PRLD

Prelude Therapeutics Incorporated

NasdaqGSUSDEQUITY DELAYED

6.69

▲ 0.19 (2.92%)

MARKET · —

Price

Open

6.51

Prev close

6.50

Day high

6.82

Day low

6.40

Volume

510.08K

Market cap

—

P/E (TTM)

—

52W range

0.98 – 6.82

Trailing performance

Price return · vs SPY

Returnvs SPY

+19.46% +20.8%

+68.70% +65.0%

+53.12% +50.0%

+138.49% +127.4%

YTD

+128.62% +116.3%

+531.43% +511.4%

+85.71% +11.5%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

5.71

+17.20% from price

SMA 20

5.15

+28.74% from price

SMA 50

4.73

+40.04% from price

SMA 100

4.52

+47.89% from price

SMA 200

3.40

+95.16% from price

EMA 12

5.67

+18.05% from price

EMA 26

5.20

+28.78% from price

EMA 50

4.85

+37.96% from price

RSI (14)

75.1

Overbought

MACD (12,26,9)

0.47

Hist 0.16

ATR (14)

0.45

6.72% of price

Realised vol 30D

90.2%

Annualised

Bollinger upper

6.54

20, 2σ

Bollinger lower

3.76

20, 2σ

50 / 200 cross

Golden

4.73 vs 3.40

Trend bias

Above 200

+95.16%

Risk profile

Daily returns · 1Y window

Beta vs SPY

2.04

More volatile than market

Correlation to SPY

0.13

Largely independent

Realised vol 30D

90.2%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-70.1%

Peak to trough

Max drawdown 5Y

-98.4%

Peak to trough

ATR 14

0.45

6.72% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 6.69

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

PRLD · links out to the publisher

Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential Stocktwits · 10d ago Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 11d ago Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High? Zacks · 22d ago Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why Zacks · 36d ago Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) Insider Monkey · 83d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.